ESR1 and breast carcinoma: Meanwhile, patients with GPVs in BRCA2 are associated with a family history of leukemia or male breast cancer, lymph node metastasis (56.82% in BRCA2 carriers vs. 38.01% in non-carriers, p = 4.0 × 10− 5), more positive cases in ER and PR (81.06% and 81.06% for BRCA2 carriers vs. 67.83% and 66.94%for non-carriers, p = 7.8 × 10− 3 and 2.3 × 10− 3, respectively), and more wild-type P53 (41.7% for BRCA2 carriers vs. 26.8% for non-carriers, p = 4.1 × 10− 4).